Cargando…

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

BACKGROUND: Docetaxel is the standard first-line agent for the treatment of androgen-independent prostate cancer (AIPC). The combination of docetaxel with molecularly targeted therapies may offer the potential to increase the efficacy and decrease the toxicity of cytotoxic chemotherapy for prostate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gross, Mitchell, Higano, Celestia, Pantuck, Allan, Castellanos, Olga, Green, Erica, Nguyen, Koo, Agus, David B
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1941739/ https://www.ncbi.nlm.nih.gov/pubmed/17662137 http://dx.doi.org/10.1186/1471-2407-7-142

Ejemplares similares

Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling
por: Hirata, Yoshito, et al.
Publicado: (2018)

Potential use of custirsen to treat prostate cancer
por: Higano, Celestia S
Publicado: (2013)

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
por: Mirjolet, Céline, et al.
Publicado: (2017)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review
por: Chen, Long, et al.
Publicado: (2014)

Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study
por: Cherrier, Monique M, et al.
Publicado: (2010)

Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy
por: Hirata, Yoshito, et al.
Publicado: (2015)

Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis
por: Mostaghel, Elahe A., et al.
Publicado: (2014)

Preliminary Development of a Mindfulness-Based Group Therapy to Expand Couples’ Sexual Intimacy after Prostate Cancer: A Mixed Methods Approach
por: Bossio, Jennifer A., et al.
Publicado: (2021)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Jang, Ho Seong, et al.
Publicado: (2016)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Assessing the nutritional needs of men with prostate cancer
por: McLaughlin, Kaitlin, et al.
Publicado: (2019)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
por: Halabi, Susan, et al.
Publicado: (2020)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation
por: Graff, Julie N, et al.
Publicado: (2015)

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)
por: Ganzinelli, Monica, et al.
Publicado: (2015)

Mechanisms of Androgen-Independent Prostate Cancer
por: Saraon, Punit, et al.
Publicado: (2014)

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
por: Henzler, Christine, et al.
Publicado: (2016)

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
por: Unger, Joseph M., et al.
Publicado: (2018)

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1
por: Mimeault, M, et al.
Publicado: (2013)

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility
por: Crawford, E. David, et al.
Publicado: (2017)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
por: Sinibaldi, Victoria J
Publicado: (2007)

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial
por: Morris, Michael J., et al.
Publicado: (2019)

Arsenic and Prostate Cancer: Acquiring Androgen Independence
por: Tibbetts, John
Publicado: (2005)

Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer
por: Cherrier, M. M., et al.
Publicado: (2018)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

A Review of Pomegranate in Prostate Cancer
por: Paller, Channing J., et al.
Publicado: (2017)

Augmentation of Docetaxel-Induced Cytotoxicity in Human PC-3 Androgen-Independent Prostate Cancer Cells by Combination With Four Natural Apoptosis-Inducing Anticancer Compounds
por: Ahmed, Inass A, et al.
Publicado: (2023)

Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer
por: Wen, Simeng, et al.
Publicado: (2020)

High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells
por: Xie, Jinhan, et al.
Publicado: (2016)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015)

Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Ryan, Charles J, et al.
Publicado: (2019)

Cognitive skill training improves memory, function, and use of cognitive strategies in cancer survivors
por: Cherrier, Monique M., et al.
Publicado: (2021)

Intermittent chemotherapy in metastatic androgen-independent prostate cancer
por: Beer, T M, et al.
Publicado: (2003)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

Regulation of expression of Na(+),K(+)-ATPase in androgen-dependent and androgen-independent prostate cancer
por: Blok, L J, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_vg9oji4iqqcm25d97rs993am4j